BREAST CANCER BASE

Female breast cancer is the most common malignancy in the world context, the incidence of breast cancer is rising year on year. Epidemiological data show that the United States breast cancer mortality rate has been going down, with the strengthening of the census, the rise of early breast cancer detection rate and systemic adjuvant therapy is still unknown.

More than 40 years ago, Fisher raised breast cancer is a systemic disease. Studies show about 1% to 5% of breast cancer patients receiving treatment has been found that when the metastatic lesions. Early breast cancer might have systemic micrometastases, most patients are in need of systemic medical treatment. The current treatment model has been widely accepted-conserving surgery and adjuvant treatment system has been extensively used in early breast cancer.

The 26th San Antonio Breast Cancer Conference, in the radiotherapy of breast cancer has many important studies, the specific details related to the following areas :
(1) early breast cancer after breast-conserving surgery to reduce the size of the target — part of the breast irradiation;
(2) breast cancer intensity modulated radiotherapy (IMRT);
(3) synchronization of breast cancer radiotherapy of breast cancer and non-conventional radiotherapy so.

In view of early breast cancer after breast-conserving local recurrence, and more primary tumor location, so in recent years abroad in some breast irradiation has carried out a series of clinical studies. The conference also have more coverage, mainly for breast cancer radiotherapy, radiotherapy after implantation, and the use of IMRT technology part of the breast irradiation three aspects.

The obesity to breast cancer chemotherapy patients, clinicians account of the distribution and drug toxicity, it is usually to reduce the dosage of chemotherapy drugs, but in fact, support this approach to the data is limited. Italian researchers recently found that obese patients with breast cancer to reduce the first dose chemotherapy regimen is not appropriate. The researchers collected several items of body mass index, chemotherapy dose, estrogen receptor expression and postmenopausal breast cancer patients prognosis of the randomized clinical research data. The results showed that a very high percentage of obese patients in the first chemotherapy regimen used in the dose of conventional doses of 85% or less. But their prognosis with those receiving conventional-dose chemotherapy compared to patients there was no significant difference. The latter disease-free survival and overall survival was even slightly higher than the 15.83 persons. Obese patients with conventional-dose chemotherapy has not been as expected those that have more side effects. The researchers do not recommend reducing obesity in patients with breast cancer chemotherapy dose.